Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes

Journal of Neuro-Oncology

Volumn 122, Issue 2, 2015, Pages 293-301

  Raychaudhuri, Baisakhi ^a,b   Rayman, Patricia ^a   Huang, Pengjing ^a   Grabowski, Matthew ^b   Hambardzumyan, Dolores ^a   Finke, James H ^a   Vogelbaum, Michael A ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

GBM; MDSC; Mouse model; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; SUNITINIB;

ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW; BONE MARROW CELL; BRAIN; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; CELL LINE; CHICKEN; DRUG EFFECTS; GLIOMA; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPLEEN; SURVIVAL; T LYMPHOCYTE; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; BRAIN; BRAIN NEOPLASMS; CELL LINE; CHICKENS; GLIOMA; HUMANS; INDOLES; LYMPHOCYTES, TUMOR-INFILTRATING; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASM TRANSPLANTATION; PROTEIN-TYROSINE KINASES; PYRROLES; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84940005453     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1720-6     Document Type: Article

References (30)

1. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174
2. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166(1):678–689
3. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI (2009) Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 182(9):5693–5701
4. Bingisser RM, Tilbrook PA, Holt PG, Kees UR (1998) Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 160(12):5729–5734
5. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111(8):4233–4244
6. Nagaraj S, Gabrilovich DI (2007) Myeloid-derived suppressor cells. Adv Exp Med Biol 601:213–223
7. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15(11):1311–1333
8. Wainwright DA, Nigam P, Thaci B, Dey M, Lesniak MS (2012) Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs 17(2):181–202
9. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA, Finke J (2011) Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 13(6):591–599
10. Ashman LK, Griffith R (2013) Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs 22(1):103–115
11. Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, Finke JH (2012) Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Invest 41(6–7):680–710
12. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA (2010) Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70(9):3526–3536
13. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15(6):2148–2157
14. Gan HK, Seruga B, Knox JJ (2009) Sunitinib in solid tumors. Expert Opin Investig Drugs 18(6):821–834
15. Abe F, Younos I, Westphal S, Samson H, Scholar E, Dafferner A, Hoke TA, Talmadge JE (2010) Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. Int Immunopharmacol 10(1):140–145
16. Hambardzumyan D, Parada LF, Holland EC, Charest A (2011) Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia 59(8):1155–1168
17. Ko JS, Bukowski RM, Fincke JH (2009) Myeloid-derived suppressor cells: a novel therapeutic target. Curr Oncol Rep 11(2):87–93
18. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190(7):3783–3797
19. Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR, Okada H (2013) Granulocyte macrophage-colony stimulation factor promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-alpha. Cancer Res 72:6413–6423
20. Dalton JE, Maroof A, Owens BM, Narang P, Johnson K, Brown N, Rosenquist L, Beattie L, Coles M, Kaye PM (2010) Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J Clin Invest 120(4):1204–1216
21. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69(6):2514–2522
22. Murdoch C, Muthana M, Coffelt SB, Lewis SE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008(8):618–631
23. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69(6):2506–2513
24. Jochems C, Schlom J (2011) Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 236(5):567–579
25. Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA (2013) Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol 111(1):41–48
26. Pan E, Yu D, Yue B, Potthast L, Chowdhary S, Smith P, Chamberlain M (2012) A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol 110(1):111–118
27. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1):327–337
28. Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ (2010) Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 129(9):2158–2170
29. Verschuere T, Toelen J, Maes W, Poirier F, Boon L, Tousseyn T, Mathivet T, Gerhardt H, Mathieu V, Kiss R, Lefranc F, Van Gool SW, De Vleeschouwer S (2014) Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Int J Cancer 134(4):873–874
30. Abad C, Nobuta H, Li J, Kasai A, Yong WH, Waschek JA (2014) Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J Leukoc Biol 95(2):357–367